MetLife Investment Advisors LLC acquired a new stake in shares of CME Group Inc (NASDAQ:CME) in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund acquired 105,289 shares of the financial services provider’s stock, valued at approximately $15,377,000.
Other large investors also recently made changes to their positions in the company. ARK Investment Management LLC purchased a new position in CME Group during the fourth quarter valued at $120,000. Valeo Financial Advisors LLC purchased a new position in CME Group during the third quarter valued at $124,000. AlphaOne Investment Services LLC purchased a new position in CME Group during the fourth quarter valued at $146,000. Mosaic Family Wealth LLC purchased a new position in CME Group during the fourth quarter valued at $146,000. Finally, Truewealth LLC purchased a new position in CME Group during the fourth quarter valued at $157,000. Institutional investors and hedge funds own 83.09% of the company’s stock.
In other CME Group news, CFO John W. Pietrowicz sold 7,500 shares of the business’s stock in a transaction dated Tuesday, January 9th. The stock was sold at an average price of $151.50, for a total transaction of $1,136,250.00. Following the completion of the sale, the chief financial officer now owns 32,376 shares of the company’s stock, valued at $4,904,964. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Ronald A. Pankau sold 200 shares of the business’s stock in a transaction dated Wednesday, February 14th. The shares were sold at an average price of $159.91, for a total value of $31,982.00. Following the sale, the director now directly owns 3,809 shares of the company’s stock, valued at approximately $609,097.19. The disclosure for this sale can be found here. Insiders sold 40,699 shares of company stock valued at $6,266,062 in the last ninety days. 0.57% of the stock is currently owned by corporate insiders.
Shares of CME Group Inc (NASDAQ:CME) opened at $163.54 on Tuesday. The company has a quick ratio of 1.03, a current ratio of 1.03 and a debt-to-equity ratio of 0.10. CME Group Inc has a fifty-two week low of $114.82 and a fifty-two week high of $171.71. The company has a market capitalization of $56,204.37, a price-to-earnings ratio of 13.70, a P/E/G ratio of 2.45 and a beta of 0.54.
CME Group (NASDAQ:CME) last issued its quarterly earnings data on Thursday, February 1st. The financial services provider reported $1.12 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $1.10 by $0.02. CME Group had a return on equity of 7.68% and a net margin of 111.49%. The company had revenue of $900.00 million during the quarter, compared to analyst estimates of $886.85 million. During the same quarter in the previous year, the company posted $1.14 earnings per share. CME Group’s revenue was down 1.4% compared to the same quarter last year. analysts forecast that CME Group Inc will post 6.41 EPS for the current fiscal year.
The company also recently disclosed a quarterly dividend, which will be paid on Monday, March 26th. Investors of record on Friday, March 9th will be issued a $0.70 dividend. The ex-dividend date of this dividend is Thursday, March 8th. This represents a $2.80 annualized dividend and a dividend yield of 1.71%. This is a positive change from CME Group’s previous quarterly dividend of $0.66. CME Group’s payout ratio is presently 23.45%.
CME has been the subject of a number of research analyst reports. ValuEngine lowered CME Group from a “buy” rating to a “hold” rating in a report on Wednesday, March 7th. Zacks Investment Research lowered CME Group from a “buy” rating to a “hold” rating in a report on Tuesday, March 6th. Bank of America lifted their target price on CME Group from $175.00 to $185.00 and gave the stock a “buy” rating in a report on Thursday, March 8th. BidaskClub lowered CME Group from a “strong-buy” rating to a “buy” rating in a report on Thursday, March 15th. Finally, Barclays lifted their target price on CME Group from $170.00 to $175.00 and gave the stock an “overweight” rating in a report on Friday, February 2nd. Five analysts have rated the stock with a hold rating and ten have assigned a buy rating to the company’s stock. The stock has an average rating of “Buy” and a consensus price target of $157.77.
COPYRIGHT VIOLATION WARNING: “MetLife Investment Advisors LLC Acquires Shares of 105,289 CME Group Inc (CME)” was published by Stock Observer and is owned by of Stock Observer. If you are reading this report on another publication, it was illegally stolen and reposted in violation of U.S. & international trademark and copyright law. The correct version of this report can be read at https://www.thestockobserver.com/2018/03/20/metlife-investment-advisors-llc-acquires-shares-of-105289-cme-group-inc-cme.html.
CME Group Company Profile
CME Group Inc, through its exchanges, provides products across all asset classes, including futures and options based on interest rates, equity indexes, foreign exchange, energy, agricultural products and metals. The Company’s segment primarily consists of the Chicago Mercantile Exchange Inc (CME), Board of Trade of the City of Chicago, Inc (CBOT), New York Mercantile Exchange, Inc (NYMEX) and Commodity Exchange, Inc (COMEX) exchanges.
Receive News & Ratings for CME Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CME Group and related companies with MarketBeat.com's FREE daily email newsletter.